Martín Varillas, José LuisSánchez Bilbao, LaraCalvo Río, VanesaAdán Civera, AlfredoHernanz, InésGallego Flores, AdelaBeltran Catalan, EmmaCastro Oreiro, SoniaFanlo, PatriciaGarcía Martos, ÁlvaroTorre, IgnacioCordero Coma, MiguelDios, Juan Ramón deGarcía Aparicio, ÁngelHernández Garfella, MarisaSánchez Andrade, AmaliaGarcía Valle, AndreaMaiz Alonso, OlgaMiguélez, RobertoRodríguez Montero, SergioUrruticoechea Arana, AnaVeroz, RaúlConesa, ArantxaFernéndez Carballido, CristinaJovaní, VegaMondejar, José J.Martínez González, OlgaMoya Alvarado, PatriciaRomero Yuste, SusanaRubio Muñoz, PaulaPeña Sainz-Pardo, EvaGarijo Bufort, MartaDemetrio Pablo, RosalíaHernández, José L.Blanco, Ricardo2024-03-272024-03-272023-07-062056-5933https://hdl.handle.net/2445/209286Objectives: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).MethodsMulticentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.ResultsWe studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6 +/- 11.7 years. The IMID included were: spondyloarthritis (n=43), Behcet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),ConclusionsCZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.7 p.application/pdfengcc by-nc (c) Martín Varillas, José Luis et al, 2022http://creativecommons.org/licenses/by-nc/3.0/es/Malalties autoimmunitàriesImmunoteràpiaAutoimmune diseasesImmunotheraphyinfo:eu-repo/semantics/article2023-07-06info:eu-repo/semantics/openAccess933927836597972